TP63 and esophageal squamous cell carcinoma: According to the multivariate analysis, AJCC stage III/IV disease and mutations in FGF3, TP63, FGF19, and FAT1 were associated with significantly increased hazard ratios among patients with ESCC (Table 1,  ∗p < 0.05).